Percent economic analysis of acquired drugs purchases through lawsuits
DOI:
https://doi.org/10.21115/JBES.v8.n2.p125-131Keywords:
judicial decisions, costs and cost analysis, pharmaceutical services, health economics, health managementAbstract
Objective: This article aims to evaluate the saving percentage of medicine acquisition from lawsuits in DRSIII (Health Regional Department) of State of São Paulo. Method: This is a descriptive study. The following data from lawsuit documents were collected: drug name, provided quantity, purchasing price and table price. Furthermore, a calculation was made to obtain unitary price, total price based on paid value and table price for each drug. In addition, the “Manual for Core Indicators on Country Pharmaceutical Situations” from WHO was applied to obtain an economic analysis. Results: The collected data from acquisition process showed a saving percentage of 51.6% (range of 2.2-99.1%). However, some items did not have a great saving such as enoxaparin and pioglitazone hydrochloride which showed a leakage of 404.4% and 139.0%, respectively. Conclusion: Most items purchased was health primary care (89.4%), showing knowledge of clinical component specialized pharmaceutical services protocols. Saving percentage of medicine acquisition is a great indicator due to it shows the purchase process efficiency and identifies which municipal had a better medicine acquisition; assisting a REMUME (Essential Medicines Municipal List) upgrade and evaluates the municipal pharmaceutical care performance.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Esta licença permite que os usuários distribuam, remixem, adaptem e criem obras derivadas a partir do material em qualquer meio ou formato, exclusivamente para fins não comerciais e desde que seja feita a devida atribuição ao criador. A licença CC BY-NC inclui os seguintes elementos:
BY: É necessário dar crédito ao criador.
NC: Somente usos não comerciais da obra são permitidos.
